These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1515 related items for PubMed ID: 15282352

  • 21. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team.
    N Engl J Med; 2009 Apr 30; 360(18):1827-38. PubMed ID: 19403902
    [Abstract] [Full Text] [Related]

  • 22. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
    Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli L, Duff F, Wang K, Nelson DR.
    Hepatology; 2008 Oct 30; 48(4):1033-43. PubMed ID: 18697207
    [Abstract] [Full Text] [Related]

  • 23. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
    Kao JH, Tung SY, Lee Y, Thongsawat S, Tanwandee T, Sheen IS, Wu JJ, Li H, Brennan BJ, Zhou J, Le Pogam S, Najera I, Thommes JA, Hill G.
    J Gastroenterol Hepatol; 2016 Oct 30; 31(10):1757-1765. PubMed ID: 26992248
    [Abstract] [Full Text] [Related]

  • 24. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML.
    Aliment Pharmacol Ther; 2008 Mar 01; 27(5):433-40. PubMed ID: 18081737
    [Abstract] [Full Text] [Related]

  • 25. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May 01; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 26. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C.
    N Engl J Med; 2012 Jan 19; 366(3):216-24. PubMed ID: 22256805
    [Abstract] [Full Text] [Related]

  • 27. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.
    Gastroenterology; 2015 Feb 19; 148(2):355-366.e1. PubMed ID: 25311593
    [Abstract] [Full Text] [Related]

  • 28. Peginterferon alfa-2a in patients with chronic hepatitis C.
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ.
    N Engl J Med; 2000 Dec 07; 343(23):1666-72. PubMed ID: 11106715
    [Abstract] [Full Text] [Related]

  • 29. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES.
    Gastroenterology; 2013 Oct 07; 145(4):790-800.e3. PubMed ID: 23811112
    [Abstract] [Full Text] [Related]

  • 30. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS.
    Gastroenterology; 2009 Feb 07; 136(2):496-504.e3. PubMed ID: 19084016
    [Abstract] [Full Text] [Related]

  • 31. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J.
    N Engl J Med; 2000 Dec 07; 343(23):1673-80. PubMed ID: 11106716
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P.
    Hepatol Int; 2017 Mar 07; 11(2):188-198. PubMed ID: 28210927
    [Abstract] [Full Text] [Related]

  • 33. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK.
    J Viral Hepat; 2007 Oct 07; 14(10):721-9. PubMed ID: 17875007
    [Abstract] [Full Text] [Related]

  • 34. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team.
    N Engl J Med; 2011 Jun 23; 364(25):2405-16. PubMed ID: 21696307
    [Abstract] [Full Text] [Related]

  • 35. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Lee CY, Chen SI, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.
    Gut; 2015 Feb 23; 64(2):303-11. PubMed ID: 24747867
    [Abstract] [Full Text] [Related]

  • 36. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H, Tatsch F.
    Ann Hepatol; 2012 Feb 23; 11(1):52-61. PubMed ID: 22166561
    [Abstract] [Full Text] [Related]

  • 37. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul 23; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J.
    J Hepatol; 2006 Jan 23; 44(1):97-103. PubMed ID: 16290907
    [Abstract] [Full Text] [Related]

  • 39. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S.
    Gastroenterology; 2005 Aug 23; 129(2):522-7. PubMed ID: 16083709
    [Abstract] [Full Text] [Related]

  • 40. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM.
    Gastroenterology; 2006 Oct 23; 131(4):1040-8. PubMed ID: 17030174
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 76.